ACROBiosystems

ACROBiosystems is a biotechnology company founded in 2010 and publicly listed in 2021. The company specializes in developing and manufacturing recombinant proteins, antibodies, assay kits, and other critical reagents to support the development of targeted therapeutics, vaccines, and diagnostics. ​

Product Portfolio:

• Recombinant Proteins: ACROBiosystems offers a comprehensive range of recombinant proteins, including cytokines, growth factors, and other signaling molecules, designed to facilitate drug development and biomedical research. ​
• Antibodies: The company provides high-quality antibodies developed through recombinant technology, ensuring specificity and reliability for applications such as immunohistochemistry, Western blotting, and ELISAs. ​
• Assay Kits: ACROBiosystems supplies various assay kits, including ELISA kits and cytokine detection kits, designed for quick and accurate analysis in research and development processes. ​

Global Presence:

With a global footprint, ACROBiosystems maintains offices, research and development centers, and production facilities in multiple cities across the United States, Switzerland, England, and Germany. The company has established long-term partnerships with leading pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, as well as renowned academic institutions.

Mission and Values:

ACROBiosystems aims to be a cornerstone of the global biopharmaceutical and health industries by providing innovative products and business models. The company is dedicated to accelerating the drug development process and contributing to global health through continuous development of new technologies and products.